Dental Implants and Diabetes
Department of Prosthodontics, Thai Moogambigai Dental College and Hospital, Chennai, India
INTRODUCTION
Diabetes is a metabolic disorder associated with carbohydrate metabolism in which high sugar level is seen for a prolonged period of time.it is due to either pancreas not producing enough insulin or diminished body cell response to insulin. here are three main types of diabetes mellitus
Type 1 Diabetes - results from the pancreas's failure to produce enough insulin. This form was previously referred to as "insulin-dependent diabetes mellitus" (IDDM) or "juvenile diabetes". The cause is unknown.
Type 2 Diabetes -begins with insulin resistance, a condition in which cells fail to respond to insulin properly. As the disease progresses a lack of insulin may also develop. This form was previously referred to as "non-insulin-dependent diabetes mellitus" (NIDDM) or "adult-onset diabetes". The most common cause is excessive body weight and insufficient exercise.
Gestational diabetes- is the third main form and occurs when pregnant women without a previous history of diabetes develop high blood sugar levels.1,2
As of 2015, an estimated 415 million people had diabetes worldwide3, with type 2 DM making up about 90% of the cases. 4 This represents 8.3% of the adult population, with equal rates in both women and men.5 As of 2014, trends suggested the rate would continue to rise. The global prevalence of diabetes. Among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014.6
DIABETES AND BONE METABOLISM
Diabetes patients generally have normal bone mineral density, indicating abnormality in bone material strength and/or bone microarchitecture7. a study was done regarding this using high resolution peripheral quantitative computed tomography (HRPQCT) has showed an elevated level of cortical porosity in Type 2 diabetes. A study was also done to see trabecular bone score, which is done using texture parameter that evaluates pixel grey level demonstrated low trabecular bone scoring.8
There are several mechanisms by which diabetes can affect bone metabolism:
- Hyperglycemia - Hyperglycemia can change the bone density through many different mechanisms.
- Toxic effect of increased glucose level can directly influence by reduction in number and function of osteoblast
- High level of glucose can cause osteoblast gene suppression through osmotic and non-osmotic pathways this results in reduced modeling of bone.
- Reduced function of osteoblast can reduce vitamin D receptor function.
- Oxidative stress: accumulation of AGEs can produce oxidative stress9
- High levels of glucose causes increased differentiation of bone marrow mesenchymal cells into adipocytes which increases abiogenesis and reduces osteogenesis
2.Insulin10
- insulin like growth factor-1 (IGF-1) and insulin causes production and differentiation of osteoblast through direct and indirect ways
- direct is through receptors present on osteoblast
- indirect is through effects on parathyroid hormone (PTH), IGF-1 and vitamin D.
3.calcium, vitamin D and calciotrophic hormones
- calcium is very important in bone metabolism therefore any change in balance between systemic condition and calcium metabolism will cause poor bone production. Calcium metabolism in diabetic patient has many reasons one of the most common is the increased release of calcium from renal system which is due to poor binding animal studies have shown tenfold increase than normal.
- Vitamin D is one of the main pathological cause of diabetes, vitamin D deficiency is risk factor for diabetes but there is still debate that vitamin D is consequence of diabetes or a predisposing factor
- animal studies have shown that serum levels of PTH, vitamin D, calcium, Mg and Phosphate are lower in diabetic models than controls, treatment with PTH protein in mice caused production of mature osteoblast and reversed trabecular bone loss. This shows modulatory and stimulatory function of PTH in osteogenesis.
4.Inflammation11
Inflammation is one of main evidence of onset of type 1 diabetes. Local and systematic inflammatory cytokines are increased and simultaneously osteoblast inhibition and adiposities are increased.
5.VasculopathyMicroangiopathy is one of the cause for bone loss in diabetes.
6.Anti-diabetic agents12
- positive effect- Metformin and sulfonylurea showed increased osteogenic activity through proliferation and differentiation of osteoblast
- Agents with negative effects- pioglitazone and rosiglitazone decrease osteoblast maturation through bone marrow and increased adipocytes count.
GLYCEMIC CONTROL
it is the most important consideration of implant patient with diabetes, while there are several other methods available HbA1c level is most frequently used, therapeutically method of measuring blood glucose level.
The HbA1c represents the percentage of non- non-enzymatically glycated A1c hemoglobin in red blood cells. Based on circulation of red blood cell that is 60-90 days which reflects average blood glucose exposed over 2-3 months therefore gives most important target in management of diabetes. An HbA1c of 6.5% is recommended as the cut point for diagnosing diabetes. A value of less than 6.5% does not exclude diabetes diagnosed using glucose tests.
With HbA1c a person can avoid problems of daily variability of values and avoids need to fast and have to precede dietary arrangement. This advantages aids in early diagnosis and treatment planning which is now strongly advocated these days.
Some of the factors that influence HbA1c and its measurement. Adapted from Gallagher et al13
1. Erythropoiesis
Increased HbA1c: iron, vitamin B12 deficiency, decreased erythropoiesis.
Decreased HbA1c: administration of erythropoietin, iron, vitamin B12,
reticulocytosis, chronic liver disease.
2. Altered Hemoglobin
Genetic or chemical alterations in haemoglobin: haemoglobinopathies,
HbF, methaemoglobin, may increase or decrease HbA1c.
3. Glycation
Increased HbA1calcoholism, chronic renal failure, decreased intraerythrocyte pH.
Decreased HbA1c: aspirin, vitamin C and E, certain
haemoglobinopathies, increased intra-erythrocyte pH.
Variable HbA1c: genetic determinants.
4. Erythrocyte destruction
Increased HbA1c: increased erythrocyte life span: Splenectomy.
Decreased A1c: decreased erythrocyte life span: haemoglobinopathies,
splenomegaly, rheumatoid arthritis or drugs such as antiretroviral,
ribavirin and dapsone.
5. Assays
Increased HbA1c: hyperbilirubinaemia, carbamylated haemoglobin,
alcoholism, large doses of aspirin, chronic opiate use.
Variable HbA1c: haemoglobinopathies.
Decreased HbA1c: hypertriglyceridaemia
Advantages and disadvantage of assays for glucose and HbA1c
Since diabetes mellitus is a relative contraindication for dental implant therapy, person’s level of glycemic control, many persons with diabetes may be denied the benefits of implant therapy. Implant placed in elevated hyperglycemic level show significant outcome after one year of loading, but early bone healing and stability may be affected by hyperglycemia so initial clinical management may be required.
A study was done where 42 implants were placed in 20 people whose hba1c level ranged from 4.7-12.6%. and showed group were significantly different from those of the low-HbA1c group. They stated that “persons with HbA1c levels ≥ 8.1% have compromises in implant stabilization that suggest alterations in the biologic integration of the implants in direct relation to glycemic control”14
OSSEOINTEGRATION OF DENTAL IMPLANTS AND DIABETES
success of implant depends on implant to bone contact. Normal bone healing occurs due to mineral metabolism which is altered in diabetes. advanced glycosylation end products (AGE) is the main cause of delayed or impaired bone healing which is end product glycosylation. early implant failure is due to loading early in these reduced bone to implant contact. immature bone, or incorrectly formed bone
In an animal study type 1 diabetes showed reduced bone to implant contact and decreased trabecular bone volume compared non diabetic animals. Cortical bone remained un affected in type 2 diabetes trabecular bone showed no differences between the groups.3 weeks following the implant diabetic rat showed 50 percent bone loss and increase in adipose cells and decrease in bone density around implant was found compared to non-diabetic rats. 15 These studies demonstrate that there was immature and disorganized bone formation of bone around implants in diabetic’s study group. Diabetic patients experience delayed wound healing, which logically affects the osseointegration process. Immature bone formation was seen in trabecular bone however cortical bone remained normal which can be used as favorable area when required and t treating the hyperglycemia and maintaining near-normal glucose levels.
SURVIVAL OF IMPLANT IN DIABETES
Survival of implants depends of level of elevated glucose level, duration of hyperglycemia and maintenance of the same. Several studies have proven that implant placed in diabetics showed success rate and failure is some time not associated with the existing condition, however proper control and measure implants showed good success rate even though the bone is in compromised condition that is why diabetes is relative contraindication for implant placement.
F. Marchand et al. has said that implant surgery is never a matter of urgency careful evaluation and removal of co morbidities such as smoking, poor oral hygiene, periodontitis should be first eradicated. hba1c level around 7 % and prevention against infection has given success rate of implant in diabetes is 85-95%.16
In a systematic revive by Heber Arbildo et al. survival rate of dental implants in controlled diabetic patients in past 10 years The overall survival rate of dental implants in diabetic controlled patients was 97.43% almost equal to non-diabetic patients. Influence of supportive therapy such prophylactic antibiotics and using chlorhexidine mouth wash improved survival rate up to 9%.17
DISCUSSION
Several studies done with implant placement in diabetes patient has shown positive results this is the reason why diabetes is not an absolute contraindicated for implants although the healing of site greatly differs from non-diabetes this may because several factors diminishing the metabolism directly or indirectly such as inflammation, oxidative stress due to AGE deposition, Vasculopathy, decreased osteoblastic activity and maturation of osteoblast, some anti-diabetic agents such aspioglitazone and rosiglitazone reduce osteoblastic activity, increased glucose level also causes osteoblastic gene suppression.. these factors can be well control with proper management of diabetes systematically. Physician consent and pre-operative evaluation should be done and post-operative management such as antibiotic prophylaxis, 0.12% chlorhexidine mouth wash, stopping of habits if present these adjuvant therapies greatly improves the outcome of the treatment.
Post-operative adjuvant therapy includes
- Caseation of any habits because studies have shown deliberating effect of smoking on implant stability
- HbA1c > 7%
- Antibiotic prophylaxis after the surgery
- Chlorhexidine mouth wash
- Regular clinical and radiographic evaluation
CONCLUSION
diabetes is an immunocompromised state where healing is affected with decreased mineral metabolic activity metabolic activity. Patient with diabetes is relative contraindication for implant placement. However, healing of site is compromised through delayed or immature bone formation compromising bone to implant contact. Proper evaluation of patient present condition and newer diagnostic modalities should be undertaken. Patients duration and percentage of hyperglycemia should be properly evaluated these factors play major role in implant stability in long run. several studies have shown good success rates in implant placed in diabetic individual there whenever possible patient who are candidate for an implant should be properly evaluated and the factor controlling the healing should be frequently monitored and proper post-operative care should be given, with these aim an implant placed in diabetic patient will show more success rate.
REFERENCES
- "Diabetes Fact sheet ". WHO. October 2013.
- Tripathy BB, Chandalia HB, Das AK. RSSDI textbook of diabetes mellitus. JP Medical Ltd; 2012 Jan 15.
- "Update 2015". ID F. International Diabetes Federation. p. 13.
- Williams textbook of endocrinology (12th ed.). Elsevier/Saunders. pp. 1371–1435. ISBN 978-1-4377-0324-5.
- Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. (December 2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2163–96. doi:10.1016/S0140-6736(12)61729-2. PMID 23245607.
- "Annual Report 2014" (PDF). IDF. International Diabetes Federation. Archived from the original (PDF) on 17 October 2016.
- . Farr JN, Khosla S. Determinants of bone strength and quality in diabetes mellitus in humans. Bone 2015; pii: S8756- 3282(15)00301-4. [Epub ahead of print] DOI: http://dx.doi. org/10.1016/j.bone.2015.07.027
- Patsch, J. M., Burghardt, A. J., Yap, S. P., Baum, T., Schwartz, A. V., Joseph, G. B., & Link, T. M. (2013). Increased Cortical Porosity in Type-2 Diabetic Postmenopausal Women with Fragility Fractures. Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research, 28(2), 313–324.
- Weinberg E, Maymon T, Weinreb M. Ages induce caspase-mediated apoptosis of rat bmscs via tnfalpha production and oxidative stress. J Mol Endocrinol. 2014;52(1):67
- Cunha JS, Ferreira VM, Maquigussa E, Naves MA, Boim MA. Effects of high glucose and high insulin concentrations on osteoblast function in vitro. Cell Tissue Res. 2014;358(1):249–5
- Bending D, Zaccone P, Cooke A. Inflammation and type one diabetes. Int Immunol. 2012;24(6):339–46.
- Hegazy SK. Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women. J Bone Miner Metab. 2015;33(2):207–12
- Gallagher EJ, Bloomgarden ZT, Le Roith D. Review of hemoglobin A1c in the management of diabetes. Journal of Diabetes, 2009, 1:9-17.
- Oates TW, Dowell S, Robinson M, McMahan CA. Glycemic control and implant stabilization in type 2 diabetes mellitus. Journal of dental research. 2009 Apr;88(4):367-71.
- Nevins ML, Karimbux NY, Weher HP, Giannobile WV, Fioruni JP. Wound healing around endosseous implants in experimental diabetes. Int J Oral Maxillofac Implants 1998;13:620‑9.
- Marchand, F., Raskin, A., Dionnes-Hornes, A., Barry, T., Dubois, N., Valéro, R. and Vialettes, B., 2012. Dental implants and diabetes: conditions for success. Diabetes & metabolism, 38(1), pp.14-19.
- Arbildo, H.I., Lamas, C.A., Camara, D. and Vásquez, H., 2015. Dental implant survival rate in well-controlled diabetic patients. A systematic review. Journal of Oral Research, 4(6), pp.404-410.
Disclaimer from Guident
The views and opinions expressed in articles published in Guident are solely those of the authors and do not necessarily reflect the views of the editors, the editorial board or the publisher, Ivory India. Guident does not endorse any product, technique or treatment described. Clinical content is intended for qualified dental and medical professionals and is not a substitute for individual clinical judgement. Guident, its editors and the publisher accept no liability for any consequence arising from the use of information published in the journal.
How to cite this article
Dr. Raul.B, Dr. Rathika Rai, Dr.B.Eswaram. Dental Implants and Diabetes. Guident. 2018 Oct;11(11). Available from: https://ivoryindia.in/articles/implantology/dental-implants-and-diabetes.html









